Free Trial

41,544 Shares in Electromed, Inc. $ELMD Bought by Isthmus Partners LLC

Electromed logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Isthmus Partners LLC initiated a position in Electromed during the third quarter, purchasing 41,544 shares worth approximately $1.17 million, or about 0.50% of the company.
  • Other institutional investors also increased or initiated holdings, with institutional ownership reaching 40.82% of Electromed’s outstanding stock.
  • Analyst sentiment remains favorable, with a consensus rating of “Moderate Buy” and an average price target of $43.75, despite shares opening at $26.87 and trading below their 50- and 200-day moving averages.
  • Five stocks to consider instead of Electromed.

Isthmus Partners LLC bought a new position in Electromed, Inc. (NYSE:ELMD - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 41,544 shares of the company's stock, valued at approximately $1,173,000. Isthmus Partners LLC owned about 0.50% of Electromed as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in ELMD. Legal & General Group Plc acquired a new position in Electromed during the second quarter valued at approximately $82,000. SG Americas Securities LLC lifted its stake in shares of Electromed by 51.5% in the first quarter. SG Americas Securities LLC now owns 5,905 shares of the company's stock worth $138,000 after buying an additional 2,007 shares during the last quarter. IFP Advisors Inc lifted its stake in shares of Electromed by 101.0% in the second quarter. IFP Advisors Inc now owns 4,023 shares of the company's stock worth $170,000 after buying an additional 2,022 shares during the last quarter. Gabelli Funds LLC lifted its stake in shares of Electromed by 10.9% in the first quarter. Gabelli Funds LLC now owns 40,700 shares of the company's stock worth $953,000 after buying an additional 4,000 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Electromed by 49.3% during the 1st quarter. Bank of America Corp DE now owns 17,059 shares of the company's stock worth $399,000 after buying an additional 5,634 shares during the period. Institutional investors own 40.82% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Morgan Stanley set a $50.00 target price on shares of Electromed in a research note on Wednesday, August 26th. Zacks Research lowered shares of Electromed from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 13th. Finally, Lake Street Capital boosted their target price on shares of Electromed from $36.00 to $47.00 and gave the stock a "buy" rating in a research report on Wednesday, August 26th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, Electromed has a consensus rating of "Moderate Buy" and an average target price of $43.75.

Read Our Latest Research Report on Electromed

Electromed Stock Down 1.6%

ELMD opened at $26.87 on Friday. The firm has a market capitalization of $222.67 million, a P/E ratio of 35.83 and a beta of 0.40. The stock's 50 day moving average price is $29.77 and its two-hundred day moving average price is $33.89. Electromed, Inc. has a 12-month low of $23.01 and a 12-month high of $47.40.

Electromed Profile

(Free Report)

Electromed, Inc is a medical device company that develops, manufactures and distributes airway clearance systems. Its products are designed to help loosen and mobilize pulmonary secretions, supporting airway clearance for patients with chronic respiratory conditions.

The company's principal product is the SmartVest Airway Clearance System, an inflatable vest system that uses high-frequency chest wall oscillation (HFCWO) technology. SmartVest systems are used in the management of conditions such as bronchiectasis, cystic fibrosis, neuromuscular disorders and other diseases associated with impaired mucus clearance.

See Also

Want to see what other hedge funds are holding ELMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Electromed, Inc. (NYSE:ELMD - Free Report).

Institutional Ownership by Quarter for Electromed (NYSE:ELMD)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Electromed Right Now?

Before you consider Electromed, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Electromed wasn't on the list.

While Electromed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines